Summit Common Stock Total Equity from 2010 to 2024
| SMMT Stock | USD 18.94 0.26 1.35% |
Common Stock Total Equity | First Reported 2014-09-30 | Previous Quarter 829 K | Current Value 974 K | Quarterly Volatility 1.1 M |
Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.3 M, Interest Expense of 17.3 M or Selling General Administrative of 31.8 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 19.78. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
Summit | Common Stock Total Equity |
Latest Summit Therapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Summit Therapeutics PLC over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Summit Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Summit Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Summit Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 3,456,492 | |
| Geometric Mean | 1,003,432 | |
| Coefficient Of Variation | 159.54 | |
| Mean Deviation | 4,174,955 | |
| Median | 826,000 | |
| Standard Deviation | 5,514,414 | |
| Sample Variance | 30.4T | |
| Range | 16.6M | |
| R-Value | (0.53) | |
| Mean Square Error | 23.4T | |
| R-Squared | 0.28 | |
| Significance | 0.04 | |
| Slope | (658,174) | |
| Total Sum of Squares | 425.7T |
Summit Common Stock Total Equity History
About Summit Therapeutics Financial Statements
Summit Therapeutics shareholders use historical fundamental indicators, such as Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Summit Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Summit Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 743.4 K | 706.2 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.